sarpogrelate has been researched along with pioglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S | 1 |
| Hamaue, N; Hirafuji, M; Iizuka, K; Machida, T; Tsuji, M | 1 |
1 trial(s) available for sarpogrelate and pioglitazone
| Article | Year |
|---|---|
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Pioglitazone; Platelet Aggregation Inhibitors; Succinates; Thiazolidinediones | 2008 |
1 other study(ies) available for sarpogrelate and pioglitazone
| Article | Year |
|---|---|
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Cell Count; Diabetes Mellitus, Type 2; Disease Models, Animal; Drinking; Drug Therapy, Combination; Eating; Hypoglycemic Agents; Insulin; Leptin; Lipids; Male; Mice; Pioglitazone; Serotonin 5-HT2 Receptor Antagonists; Succinates; Thiazolidinediones | 2009 |